logo
US Economy Outstripped China in 2024 for Third Year in a Row

US Economy Outstripped China in 2024 for Third Year in a Row

Yahoo30-01-2025
(Bloomberg) -- The US tightened its grip on the title of world's biggest economy in 2024 as an irrepressible American consumer helped it pull away from China for a third straight year — at least by one measure.
Manhattan's Morning Commute Time Drops With New Congestion Toll
Trump's Federal Funding Pause Threatens State Financials
Housing Aid Uncertain After Trump's Spending Freeze Memo
US Students' Reading Scores Drop to Worst in More Than 20 Years
Trump Paves the Way to Deputize Local Police on Immigration
US gross domestic product increased 5.3% last year before adjusting for inflation, according to Bureau of Economic Analysis data released Thursday. In comparison, China's nominal GDP growth clocked in at 4.2%, the country's National Bureau of Statistics reported two weeks ago.
The two nations' contrasting challenges with prices in recent years help explain the widening gap between their GDP levels. The US figures are flattered by the elevated inflation rates that spurred historically aggressive Federal Reserve monetary policy tightening in 2022 and 2023. By contrast, China has been battling deflation — its so-called GDP deflator has indicated falling prices since mid-2023.
Relative sizes of economies can be measured in various ways. When adjusted for inflation, China continued to expand at a faster pace, with real GDP rising 5% — compared with 2.8% for the US. But nominal figures are often viewed as more relevant for things like corporate and government revenues and trade flows.
Typically, lesser-developed nations like China sustain faster economic growth rates as they catch up with their advanced rivals. China's GDP per capita was $12,614 in 2023, the latest year for which the World Bank has comparative data. In the US, it was $82,769 — showcasing the enormous catch-up potential for the world's No. 2. But Chinese policymakers have been struggling to contain a massive property-market slump, alongside depressed consumer confidence.
'China's economy is in the midst of a painful but necessary transition from cement to silicon as the main driver of growth,' said Tom Orlik, the chief economist at Bloomberg Economics and a longtime China watcher. 'The US continues to outperform, and in nominal terms its growth rate has been juiced by above-target inflation. The race for the world's top GDP spot is still on. For now, the US is extending its lead.'
The US also demonstrated its continuing exceptionalism against its developed-world counterparts last year. Thursday's GDP release came hours after both France and Germany reported quarterly contractions in their economies during the final three months of 2024.
Consumer spending was the biggest driver of US growth last year, fueled by wage increases and employment gains. American payrolls climbed by more than 2.2 million last year, while average hourly earnings advanced 1% in December from a year earlier after adjusting for inflation.
Trade Disparity
That US consumption has also pulled in an increasing volume of imports, widening the politically sensitive trade deficit. The merchandise trade deficit reached nearly $1.1 trillion for January through November last year, and preliminary figures for December released Wednesday showed an unprecedented monthly deficit of $122 billion.
China has been among the beneficiaries, with US imports from its geopolitical rival up 2.2% for January through November. China's own data showed the world's biggest manufacturing nation accumulated a record trade surplus of some $992 billion in 2024. While President Xi Jinping has repeatedly vowed to ramp up his nation's imports, subdued domestic demand has made that a challenging task.
How 2025 will shape up is a major question for economists and global policymakers alike, with newly installed President Donald Trump threatening to impose tariff hikes on US trading partners.
Indy Pass, the Anti-Vail Seasonal Ski Ticket, Is Gaining Fans
The Internet Almost Killed Barnes & Noble, Then Saved It
What America's Tech Billionaires Really Bought When They Backed Donald Trump
Musk Pitches New Narrative as Tesla Sales Fall
Forget Factories, Small US Towns Want Buc-ee's Gas Stations
©2025 Bloomberg L.P.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Does Neogen Corporation (NEOG) Have a Significant Upside?
Does Neogen Corporation (NEOG) Have a Significant Upside?

Yahoo

time10 minutes ago

  • Yahoo

Does Neogen Corporation (NEOG) Have a Significant Upside?

Baron Funds, an investment management company, released its 'Baron Small Cap Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter of 2025, the fund was up 10.38%% (Institutional Shares) compared to the Russell 2000 Growth Index's (the Index) 11.97% return. Year to date, the Fund is up 0.36% compared to the index's (0.48)% return. Small-cap stocks recovered well during the quarter and performed in line with the overall market but have significantly trailed larger-cap stocks this year. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Small Cap Fund highlighted stocks such as Neogen Corporation (NASDAQ:NEOG). Neogen Corporation (NASDAQ:NEOG) engages in the development of various products and services dedicated to food and animal safety. The one-month return of Neogen Corporation (NASDAQ:NEOG) was -2.68%, and its shares lost 69.06% of their value over the last 52 weeks. On August 8, 2025, Neogen Corporation (NASDAQ:NEOG) stock closed at $5.08 per share, with a market capitalization of $1.103 billion. Baron Small Cap Fund stated the following regarding Neogen Corporation (NASDAQ:NEOG) in its second quarter 2025 investor letter: "Shares of Neogen Corporation (NASDAQ:NEOG), a leading provider of food and animal safety products, detracted from performance. The company reported weak fiscal Q3 2025 earnings, lowered its fiscal 2025 guidance, and announced that its CEO will step down later this year. Several years of M&A integration and operational hiccups have cratered the stock. We expect near-term volatility to persist but retain long-term conviction. We added to our position as shares have significant upside. The company is selling non-core businesses at goal prices, which is de-levering its balance sheet and should enhance the growth profile. We are hopeful that the company is nearing the end of its transition and will revert to nice growth shortly." A research laboratory showing advanced diagnostic equipment used to protect public health. Neogen Corporation (NASDAQ:NEOG) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 15 hedge fund portfolios held Neogen Corporation (NASDAQ:NEOG) at the end of the first quarter, which was 15 in the previous quarter. While we acknowledge the potential of Neogen Corporation (NASDAQ:NEOG) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Neogen Corporation (NASDAQ:NEOG) and shared Conestoga Capital Advisors' views on the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

CMB International Securities Raised the Firm's PT on Meta Platforms (META)
CMB International Securities Raised the Firm's PT on Meta Platforms (META)

Yahoo

time10 minutes ago

  • Yahoo

CMB International Securities Raised the Firm's PT on Meta Platforms (META)

Meta Platforms, Inc. (NASDAQ:META) is one of the Good Stocks to Invest in Now. On August 1, Saiyi He from CMB International Securities raised the firm's price target on Meta Platforms, Inc. (NASDAQ:META) from $760 to $860, while maintaining a Buy rating on the stock. The analyst noted that the company's Q2 revenue grew by 22% year-over-year, driven by AI-enhanced ad impressions and pricing. Moreover, the net income grew by 36%, which was well above expectations. Saiyi noted that the management is expecting continued revenue growth in the third quarter as well, beating the market expectations. A team of developers working in unison to create the company's messaging application. The analyst highlighted that AI advancements are central to Meta Platforms, Inc.'s (NASDAQ:META) business. The company has improved AI-powered ad recommendation models, leading to better ad conversions on Facebook and Instagram. It is also investing in AI talent and infrastructure, which Saiyi believes will help the company maintain its AI leading position. Meta Platforms, Inc. (NASDAQ:META) is a tech company that connects people through social media and immersive experiences. While we acknowledge the potential of META as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143
Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143

Yahoo

time10 minutes ago

  • Yahoo

Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143

Mereo BioPharma Group plc (NASDAQ:MREO) is one of the . On July 9, Mereo BioPharma Group, along with Ultragenyx Pharmaceutical Inc., announced progress in the Phase 3 Orbit study testing UX143 for osteogenesis imperfecta. The study is moving toward a final analysis expected around the end of the year. Management noted that the Data Monitoring Committee reviewed the data and found UX143 to have an acceptable safety profile, giving them a go-ahead for the final analysis. Moreover, management also remains confident that increasing UX143 increases bone mass, leading to stronger bones, fewer fractures, and better physical abilities. A laboratory team in white coats working and testing new biopharmaceuticals. Ultragenyx's CEO, Emil D. Kakkis, noted that while they had hoped to close the trial earlier, they are eager to see complete results from the Orbit and Cosmic studies later this year. Mereo BioPharma Group plc (NASDAQ:MREO) is a biopharmaceutical company that develops medicines for rare diseases and cancer. The company is working on treatments like Setrusumab for brittle bone disease and alvelestat for severe lung disease. While we acknowledge the potential of MREO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store